AUTHOR INDEX

ACERBI, D. *see* HOUGHTON, C.M.
ADLER, R. *see* GRACH, M.
AGARWAL, S. *see* GUPTA, M.
AGERSØ, H., LARSEN, L.S., RIIS, A., LÖVGREN, U., KARLSSON, M.O. & SENDEROVITZ, T. Pharmacokinetics and renal excretion of desmopressin after intravenous administration to healthy subjects and renally impaired patients: 352
AGERTOFT, L. *see* KAAE, R.
AIACHE, J.-M. *see* CARDOT, J.-M.
ALI, R. *see* JITTIWUTIKARN, J.
ANDO, H. *see* TSURUOKA, S.
ANEJA, S. *see* GUPTA, M.
ARIYOSHI, N., SHO-NO, K., NISHIMURA, M., ITO, M., NAKAMURA, H., ASAI, T., SAITOH, Y., ISHIZAKI, T. & KITADA, M. The use of urine to clarify the genotype of a patient with toxic phenytoin concentrations who had undergone peripheral blood stem cell transplantation: 225
ARNON, J. *see* BERKOVITCH, M.
ARONSON, J.K. Classifying drug interactions: 343
ARONSON, J.K. Littluns and biguns: 117
ARONSON, J.K. Over-the-counter medicines: 231
ARONSON, J.K. *see* BABER, N.S.
ARONSON, J.K. What is a clinical trial?: 1
ARSENAULT, M. *see* SHARMA, A.
ASAI, T. *see* ARIYOSHI, N.
ATALAY, Y. *see* OKUMUS, N.

BABER, N.S., RITTER, J.M. & ARONSON, J.K. Medicines regulation and clinical pharmacology: 569
BACKMAN, J.T. *see* KAJOSAARI, L.I.
BASSI, P.U., ONYEJI, C.O. & UKPONMWAN, O.E. Effects of tetracycline on the pharmacokinetics of halofantrine in healthy volunteers: 52
BATES, C.E. *see* LEE, D.K.C.
BATTY, K.T. *see* MOHAN, M.
BAUER, S. *see* MAI, I.
BAUMANN, C.R., OTT, P.M. & SIEGEL, A.M. Hypogeusia as an adverse reaction of phenytoin: 678
BÉLANGER, P.M. *see* SHARMA, A.
BECKER, J.C., DOMSCHKE, W. & POHLE, T. Current approaches to prevent NSAID-induced gastropathy – COX selectivity and beyond: 587
BENGTSSON, T. *see* KAAE, R.
BENNETT, K. *see* ODUBANJO, E.
BENNETT, K. *see* WILLIAMS, D.
BENTZEN, C. *see* BONATE, P.L.
BERKOVITCH, M., DIAV-CITRIN, O., GREENBERG, R., COHEN, M., BULKOWSTEIN, M., SHECHTMAN, S., BORTNIK, O., ARNON, J. & ORNOY, A. First-trimester exposure to amoxycillin/clavulanic acid: a prospective, controlled study: 298
BERTELÉ, V. *see* GARATTINI, S.
BILKER, W.B. *see* HENNESSY, S.
BLOT, S. *see* VANDER STICHELE, R.H.
BOCHNER, F. *see* JITTIWUTIKARN, J.
BOCHNER, F. *see* MITCHELL, T.B.
BOLGER, C. *see* CANTARINI, M.V.
BONATE, P.L., FLORET, S. & BENTZEN, C. Population pharmacokinetics of APOMINE™: A meta-analysis in cancer patients and healthy males: 142
BORTNIK, O. *see* BERKOVITCH, M.
BOWERS, R. *see* COX, D.
BRADBURY, B.D. & JICK, H. *In vitro* fertilization and childhood retinoblastoma: 209
BRADBURY, B.D. *see* JICK, S.S.
BRECKENRIDGE, A. The changing scene of the regulation of medicines in the UK. Paper from The Use of Medicines: Regulation & Clinical Pharmacology in the 21st Century Symposium – December 2003: 571
BROUWERS, A.H.P.M. *see* DE GRAAF, L.
BROUWERS, J.R.B.J. *see* VAN ROON, E.N.
BROWN, D.M. Drug Delivery Systems in Cancer Therapy: 336
BRUYN, G.A.W. *see* VAN ROON, E.N.
BRYANT, C.A. *see* MANGONI, A.A.
BUDDE, K. *see* MAI, I.
BULKOWSTEIN, M. *see* BERKOVITCH, M.
BURGER, D.M. *see* LA PORTE, C.J.L.
BURGGRAAF, J. *see* LITJENS, N.H.R.
BURHENNE, J. *see* FRÖHLICH, M.
BURHENNE, J. *see* MARTIN-FACKLAM, M.
BUURMA, H., DE SMET, P.A.G.M., LEUFKENS, H.G.M. & EGBERTS, A.C.G. Evaluation of the clinical value of pharmacists' modifications of prescription errors: 503

CANTARINI, M.V., PAINTER, C.J., GILMORE, E.M., BOLGER, C., WATKINS, C.L. & HUGHES, A.M. Effect of oral linezolid on the pressor response to intravenous tyramine: 470
CARDOT, J.-M., CHAUMONT, C., DUBRAY, C., COSTANTINI, D. & AIACHE, J.-M. Comparison of the pharmacokinetics of miconazole after administration via a bioadhesive slow release tablet and an oral gel to healthy male and female subjects: 345
CHAN, J.C.N. *see* CHENG, C.W.R.
CHAN, Y.H. *see* SIM, K.
CHAUMONT, C. *see* CARDOT, J.-M.
CHENG, C.W.R., WOO, K.-S., CHAN, J.C.N., TOMLINSON, B. & YOU, J.H.S. Association between adherence to statin therapy and lipid control in Hong Kong Chinese patients at high risk of coronary heart disease: 528
CHONG, M.-Y. *see* SIM, K.
CHOONARA, I., DEWIT, O., HARROP, E., HOWARTH, S., HELMS, P., KANABAR, D., LENNEY, W., RYLANCE, G. & VALLANCE, P. Training in paediatric clinical pharmacology in the UK: 217
CHRISTOPHERSEN, A.S. *see* OLSEN, L.
CHUNG, E.K. *see* SIM, K.
CILISSEN, J. *see* VAN OPSTAL, J.M.
CLOSE, J.C.T. *see* MANGONI, A.A.
COCKCROFT, J.R. *see* SHARMAN, J.E.
COHEN, M. *see* BERKOVITCH, M.
COLBERS, E.P.H. *see* LA PORTE, C.J.L.
COLLIER, P.S. *see* SMYTH, J.M.
COOMBES, J.S. *see* SHARMAN, J.E.
COOPER, J.A. *see* MOHAN, M.
CORYNEN, S. *see* DIETERLE, W.
COSTANTINI, D. *see* CARDOT, J.-M.
COX, D., BOWERS, R. & MCBRIDE, A. Reboxetine may be helpful in the treatment of amphetamine withdrawal: 100
CRAIG, C.R. & STITZEL, R.E. Modern Pharmacology with Clinical Applications, 6th edn: 337
CREAN, A.M. & POHL, J.E.F. 'Ally McBeal heart?' – Drug induced cardiomyopathy in a young woman: 558
CURRIE, G.P. *see* LEE, D.K.C.

DALE, O., SHEFFELS, P. & KHARASCH, E.D. Bioavailabilities of rectal and oral methadone in healthy subjects: 156
DARWISH, M. *see* SMYTH, J.M.
DE ABAJO, F.J., MONTERO, D., MADURGA, M. & RODRÍGUEZ, L.A.G. Acute and clinically relevant drug-induced liver injury: a population based case-control study: 71
DE BOER, A. *see* MANTEL-TEEUWISSE, A.K.
DE GRAAF, L., BROUWERS, A.H.P.M. & DIEMONT, W.L. Is decreased libido associated with the use of HMG-CoA-reductase inhibitors?: 326
DE GRAAFF-TEULEN, M.J.A. *see* LA PORTE, C.J.L.

© 2004 Blackwell Publishing Ltd

DE HEER, F. *see* VAN OPSTAL, J.M.
DE SMET, P.A.G.M. *see* BUURMA, H.
DELDOT, M.E., LIPMAN, J. & TETT, S.E. Vancomycin pharmacokinetics in critically ill patients receiving continuous venovenous haemodiafiltration: 259
DESTA, Z. *see* WARD, B.A.
DESTEFANO, A.J. *see* MOUELHI, M.E.
DEWIT, O. *see* CHOONARA, I.
DIAV-CITRIN, O. *see* BERKOVITCH, M.
DIEMONT, W.L. *see* DE GRAAF, L.
DIETERLE, W., CORYNEN, S. & MANN, J. Effect of the oral renin inhibitor aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy subjects: 433
DOMSCHKE, W. *see* BECKER, J.C.
DUBRAY, C. *see* CARDOT, J.-M.
DUFFULL, S.B. *see* GREEN, B.
DYER, K.R. *see* MITCHELL, T.B.

EDENIUS, C. *see* ZINGMARK, P.-H.
EGBERTS, A.C.G. *see* BUURMA, H.
EISENBERG, E. *see* GRACH, M.
ELLIOTT, R. *see* SORENSEN, L.
ELSEVIERS, M.M. *see* VANDER STICHELE, R.H.
ERNSTGÅRD, L., WARHOLM, M. & JOHANSON, G. Robustness of chlorzoxazone as an *in vivo* measure of cytochrome P450 2E1 activity: 190
EVE, M. *see* SOBUE, S.

FEELY, J. *see* ODUBANJO, E.
FEELY, J. *see* WILLIAMS, D.
FERECH, M. *see* VANDER STICHELE, R.H.
FIGULLA, H.R. *see* GOERNIG, M.
FILLER, G. *see* MAI, I.
FLOCKHART, D.A. *see* WARD, B.A.
FLORET, S. *see* BONATE, P.L.
FONTANA, G.A. *see* LAVORINI, F.
FOSTER, D.J.R. *see* JITTIWUTIKARN, J.
FRICKER, R., HESSE, C., WEISS, J., TAYROUZ, Y., HOFFMANN, M.M., UNNEBRINK, K., MANSMANN, U. & HAEFELI, W.E. Endothelial venodilator response in carriers of genetic polymorphisms involved in NO synthesis and degradation: 169
FRÖHLICH, M., HOFFMANN, M.M., BURHENNE, J., MIKUS, G., WEISS, J. & HAEFELI, W.E. Association of the *CYP3A5* A6986G (*CYP3A5*3*) polymorphism with saquinavir pharmacokinetics: 443
FROGOPSAHL, G. *see* OLSEN, L.
FUJII, S. *see* SIM, K.
FUJIMURA, A. *see* KAWAGUCHI, A.
FUJIMURA, A. *see* TSURUOKA, S.

GALINSKY, R.E. *see* WARD, B.A.
GARATTINI, S. & BERTELÉ, V. Risk: benefit assessment of old medicines: 581
GERI, P. *see* LAVORINI, F.
GIESCHKE, R. *see* PILLAI, G.
GILLESPIE, N.D. *see* WITHAM, M.D.
GILMORE, E.M. *see* CANTARINI, M.V.
GLASSER, D.B. *see* HENNESSY, S.
GOERNIG, M., KIRMEIER, T., KRACK, A., HARTOG, C.S., FIGULLA, H.R. & LEDER, U. Iohexol contrast medium induces QT prolongation in amiodarone patients: 96
GOETTSCH, W.G., JANKNEGT, R. & HERINGS, R.M.C. Increased treatment failure after 3-days' courses of nitrofurantoin and trimethoprim for urinary tract infections in women: a population-based retrospective cohort study using the PHARMO database: 184
GOGGIN, T. *see* PILLAI, G.
GOLDAMMER, M. *see* MAI, I.
GOOSSENS, H. *see* VANDER STICHELE, R.H.
GRACH, M., MASSALHA, W., PUD, D., ADLER, R. & EISENBERG, E. Can coadministration of oxycodone and morphine produce analgesic synergy in humans? An experimental cold pain study: 235
GRAY, R.D. *see* LEE, D.K.C.
GREEN, B. & DUFFULL, S.B. What is the best size descriptor to use for pharmacokinetic studies in the obese?: 119
GREENBERG, R. *see* BERKOVITCH, M.
GRIEP, E.N. *see* VAN ROON, E.N.
GRIFFIN J.P. Venetian treacle and the foundation of medicines regulation: 317
GROSS, G. *see* KRETZ, O.
GUAN, Y.-Y. *see* ZHANG, J.-P.
GUNARUWAN, P. *see* SHARMAN, J.E.
GUPTA, M., GUPTA, Y.K., AGARWAL, S., ANEJA, S. & KOHLI, K. A randomized, double-blind, placebo controlled trial of melatonin add-on therapy in epileptic children on valproate monotherapy: effect on glutathione peroxidase and glutathione reductase enzymes: 542
GUPTA, Y.K. *see* GUPTA, M.
GUTH, B.D., NARJES, H., SCHUBERT, H.-D., TANSWELL, P., RIEDEL, A. & NEHMIZ, G. Pharmacokinetics and pharmacodynamics of terbogrel, a combined thromboxane A_2 receptor and synthase inhibitor, in healthy subjects: 40
GUYATT, G. *see* MILLS, E.

HAEFELI, W.E. *see* FRICKER, R.
HAEFELI, W.E. *see* FRÖHLICH, M.
HAEFELI, W.E. *see* MARTIN-FACKLAM, M.
HAGGART, K. *see* LEE, D.K.C.
HALLIDAY, H.L. *see* SMYTH, J.M.
HAMELIN, B.A. *see* SHARMA, A.
HARADA, K. *see* KAWAGUCHI, A.
HARROP, E. *see* CHOONARA, I.
HARTOG, C.S. *see* GOERNIG, M.
HAUBEN M., & REICH, L. A case report of rhabdomyolysis with pentamidine that prompted a retrospective evaluation of a pharmacovigilance tool under investigation: 675
HAUBEN, M. & REICH, L. Drug-induced pancreatitis: lessons in data mining: 560
HAUBEN. M. Trimethoprim-induced hyperkalaemia – lessons in data mining: 338
HECKERS, S. *see* SIM, K.
HEKSTER, Y.A. *see* LA PORTE, C.J.L.
HELMS, P. *see* CHOONARA, I.
HENNESSY, S., BILKER, W.B., KNAUSS, J.S., KIMMEL, S.E., MARGOLIS, D.J., MORRISON, M.F., REYNOLDS, R.F., GLASSER, D.B. & STROM, B.L. Comparative cardiac safety of low-dose thioridazine and low-dose haloperidol: 81
HERINGS, R.M.C. *see* GOETTSCH, W.G.
HESSE, C. *see* FRICKER, R.
HOFFMANN, M.M. *see* FRICKER, R.
HOFFMANN, M.M. *see* FRÖHLICH, M.
HOLDEN, J. *see* HOUGHTON, C.M.
HOLFORD, N. *see* MATTHEWS, I.
HOUGHTON, C.M., LANGLEY, S.J., SINGH, S.D., HOLDEN, J., PRETI, A.P.M., ACERBI, D., POLI, G. & WOODCOCK, A. Comparison of bronchoprotective and bronchodilator effects of a single dose of formoterol delivered by hydrofluoroalkane and chlorofluorocarbon aerosols and dry powder in a double blind, placebo-controlled, crossover study: 359
HOUGHTON, C.M., WOODCOCK, A.A. & SINGH, D. A comparison of lung function methods for assessing dose–response effects of salbutamol: 134
HOUTMAN, P.M. *see* VAN ROON, E.N.
HOWARTH, S. *see* CHOONARA, I.
HUANG, M. *see* ZHANG, J.-P.
HUGHES, A.M. *see* CANTARINI, M.V.
HUSSAIN, T.S. *see* KAMBAL, A.

IBANEZ, S.M. *see* LA PORTE, C.J.L.
ILETT, K.F. *see* MOHAN, M.
IOKA, T. *see* TSURUOKA, S.
ISBISTER, G.K., O'REGAN, L., SIBBRITT, D. & WHYTE, I.M. Alprazolam is relatively more toxic than other benzodiazepines in overdose: 88
ISHIZAKI, T. *see* ARIYOSHI, N.
ITO, M. *see* ARIYOSHI, N.

JACKSON, S.H.D. *see* MANGONI, A.A.
JACQMIN, P. *see* PILLAI, G.
JANKNEGT, R. *see* GOETTSCH, W.G.
JANKNEGT, R. *see* VAN OPSTAL, J.M.
JANSEN, T.L.T.A. *see* VAN ROON, E.N.
JICK, H. *see* BRADBURY, B.D.
JICK, S.S. & BRADBURY, B.D. Statins and newly diagnosed diabetes: 303

JITTIWUTIKARN, J., ALI, R., WHITE, J.M., BOCHNER, F., SOMOGYI, A.A. & FOSTER, D.J.R. Comparison of tincture of opium and methadone to control opioid withdrawal in a Thai treatment centre: 536
JOHANNES-HELLBERG, I. *see* KAAE, R.
JOHANSON, G. *see* ERNSTGÅRD, L.
JOHNE, A. *see* MAI, I.

KAAE, R., AGERTOFT, L., PEDERSEN, S., NORDVALL, S.L., PEDROLETTI, C., BENGTSSON, T., JOHANNES-HELLBERG, I. & ROSENBORG, J. Cumulative high doses of inhaled formoterol have less systemic effects in asthmatic children 6–11 years-old than cumulative high doses of inhaled terbutaline: 411
KAJOSAARI, L.I., BACKMAN, J.T., NEUVONEN, M., LAITILA, J. & NEUVONEN, P.J. Lack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinide: 390
KAMBAL, A., NAJEM, M. & HUSSAIN, T.S. Multi-dosage vials, potential for overdose: 677
KANABAR, D. *see* CHOONARA, I.
KANDIL, A. *see* WARD, B.A.
KANEKO, S. *see* OSANAI, T.
KARLSSON, M.O. *see* AGERSØ, H.
KARLSSON, M.O. *see* WÄHLBY, U.
KARLSSON, M.O. *see* ZINGMARK, P.-H.
KAWAGUCHI, A., OHMORI, M., TSURUOKA, S., NISHIKI, K., HARADA, K., MIYAMORI, I., YANO, R., NAKAMURA, T., MASADA, M. & FUJIMURA, A. Drug interaction between St John's wort and quazepam: 403
KETA, H. *see* TOGAWA, A.
KHARASCH, E.D. *see* DALE, O.
KIM, K.-A. *see* PARK, J.-Y.
KIMMEL, S.E. *see* HENNESSY, S.
KIRKPATRICK, C. *see* MATTHEWS, I.
KIRMEIER, T. *see* GOERNIG, M.
KITADA, M. *see* ARIYOSHI, N.
KLUNGEL, O.H. *see* MANTEL-TEEUWISSE, A.K.
KNAUSS, J.S. *see* HENNESSY, S.
KNEZ, W.L. *see* SHARMAN, J.E.
KOBAYASHI, Y. *see* TOGAWA, A.
KOÇ, E. *see* OKUMUS, N.
KOHLI, K. *see* GUPTA, M.
KONDO, T. *see* OSANAI, T.
KOOPMANS, P.P. *see* LA PORTE, C.J.L.
KRACK, A. *see* GOERNIG, M.
KRAUWINKEL, W.J. *see* UCHIDA, T.
KRETZ, O., WEISS, H.M., SCHUMACHER, M.M. & GROSS, G. *In vitro* blood distribution and plasma protein binding of the tyrosine kinase inhibitor imatinib and its active metabolite, CGP74588, in rat, mouse, dog, monkey, healthy humans and patients with acute lymphatic leukaemia: 212
KROMHOUT, D. *see* MANTEL-TEEUWISSE, A.K.
KUBLICKAS, M. *see* LINDH, J.D.
KUKONGVIRIYAPAN, V. *see* SRIMARTPIROM, S.
KUZMAK, B. *see* MOUELHI, M.E.

L'ORTIJE, W.H.V.M. *see* VAN OPSTAL, J.M.
LA PORTE, C.J.L., DE GRAAFF-TEULEN, M.J.A., COLBERS, E.P.H., VONCKEN, D.S., IBANEZ, S.M., KOOPMANS, P.P., HEKSTER, Y.A. & BURGER, D.M. Effect of efavirenz treatment on the pharmacokinetics of nelfinavir boosted by ritonavir in healthy volunteers: 632
LAITILA, J. *see* KAJOSAARI, L.I.
LANG, C.C. *see* YANG, Y.S.
LANGLEY, S.J. *see* HOUGHTON, C.M.
LARSEN, L.S. *see* AGERSØ, H.
LAVORINI, F., GERI, P., LUPERINI, M., MALUCCIO, N.M., MARIANI, L., MARMAI, C., PISTOLESI, M. & FONTANA, G.A. Clinical and functional responses to salbutamol inhaled via different devices in asthmatic patients with induced bronchoconstriction: 512
LAYTON, G. *see* SOBUE, S.
LEDER, U. *see* GOERNIG, M.
LEE, D.K.C. & LIPWORTH, B.J. Intranasal and inhaled corticosteroids in allergic rhinitis and asthma: 447
LEE, D.K.C., GRAY, R.D., WILSON, A.M., ROBB, F.M., SOUTAR, P.C. & LIPWORTH, B.J. Single and short-term dosing effects of levocetirizine on adenosine monophosphate bronchoprovocation in atopic asthma: 34
LEE, D.K.C., HAGGART, K., CURRIE, G.P., BATES, C.E. & LIPWORTH, B.J. Effects of hydrofluoroalkane formulations of ciclesonide 400μg once daily *vs* fluticasone 250μg twice daily on methacholine hyper-responsiveness in mild-to-moderate persistent asthma: 26
LEE, K.Y. *see* PARK, J.-Y.
LEE, T.C. *see* YANG, Y.S.
LENNEY, W. *see* CHOONARA, I.
LEUFKENS, H.G.M. *see* BUURMA, H.
LILJA, J.J., NEUVONEN, M. & NEUVONEN, P.J. Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin: 56
LINDH, J.D., KUBLICKAS, M., WESTGREN, M. & RANE, A. Internet based clinical trial protocols – as applied to a study of warfarin pharmacogenetics: 482
LIPMAN, J. *see* DELDOT, M.E.
LIPWORTH, B.J. *see* LEE, D.K.C.
LIPWORTH, B.J. *see* LEE, D.K.C.
LIPWORTH, B.J. *see* LEE, D.K.C.
LITJENS, N.H.R., BURGGRAAF, J., VAN STRIJEN, E., VAN GULPEN, C., MATTIE, H., SCHOEMAKER, R.C., VAN DISSEL, J.T., THIO, H.B. & NIBBERING, P.H. Pharmacokinetics of oral fumarates in healthy subjects: 429
LÖVGREN, U. *see* AGERSØ, H.
LOKE, Y.K. *see* MILLS, E.
LUPERINI, M. *see* LAVORINI, F.

MØRLAND, J. *see* OLSEN, L.
MADURGA, M. *see* DE ABAJO, F.J.
MAI, I., PERLOFF, E.S., BAUER, S., GOLDAMMER, M., JOHNE, A., FILLER, G., BUDDE, K. & ROOTS, I. *MDR1* haplotypes derived from exons 21 and 26 do not affect the steady-state pharmacokinetics of tacrolimus in renal transplant patients: 548
MALUCCIO, N.M. *see* LAVORINI, F.
MANGONI, A.A., CLOSE, J.C.T., RODRIGUEZ, S., SHERWOOD, R.A., BRYANT, C.A., SWIFT, C.G. & JACKSON, S.H.D. Acute hypotensive effects of oral cisapride and erythromycin in healthy subjects: 223
MANN, J. *see* DIETERLE, W.
MANSMANN, U. *see* FRICKER, R.
MANTEL-TEEUWISSE, A.K., VERSCHUREN, W.M.M., KLUNGEL, O.H., DE BOER, A. & KROMHOUT, D. Recent trends in (under)treatment of hypercholesterolaemia in the Netherlands: 310
MARGOLIS, D.J. *see* HENNESSY, S.
MARIANI, L. *see* LAVORINI, F.
MARMAI, C. *see* LAVORINI, F.
MARSH, S.A. *see* SHARMAN, J.E.
MARTIN-FACKLAM, M., RIEGER, K., RIEDEL, K.-D., BURHENNE, J., WALTER-SACK, I. & HAEFELI, W.E. Undeclared exposure to St. John's wort in hospitalized patients: 437
MASADA, M. *see* KAWAGUCHI, A.
MASSALHA, W. *see* GRACH, M.
MATTHEWS, I., KIRKPATRICK, C. & HOLFORD, N. Quantitative justification for target concentration intervention – parameter variability and predictive performance using population pharmacokinetic models for aminoglycosides: 8
MATTIE, H. *see* LITJENS, N.H.R.
MCBRIDE, A. *see* COX, D.
MCELNAY, J.C. *see* SMYTH, J.M.
MIKUS, G. *see* FRÖHLICH, M.
MILLERSHIP, J.S. *see* SMYTH, J.M.
MILLIGAN, P.A. *see* WÄHLBY, U.
MILLS, E., LOKE, Y.K., WU, P., MONTORI, V.M., PERRI, D., MOHER, D. & GUYATT, G. Determining the reporting quality of RCTs in clinical pharmacology: 61

MITCHELL, T.B., DYER, K.R., NEWCOMBE, D., SALTER, A., SOMOGYI, A.A., BOCHNER, F. & WHITE, J.M. Subjective and physiological responses among racemic-methadone maintenance patients in relation to relative (S)- *vs.* (R)-methadone exposure: 609
MIYAMORI, I. *see* KAWAGUCHI, A.
MOFFATT, A.C., OSSELTON, M.D. & WIDDOP, B. Clarke's Analysis of Drugs and Poisons, 3rd Edition: 99
MOHAMED, Z. *see* YANG, Y.S.
MOHAN, M., BATTY, K.T., COOPER, J.A., WOJNAR-HORTON, R.E. & ILETT, K.F. Comparison of gentamicin dose estimates derived from manual calculations, the Australian 'Therapeutic Guidelines: Antibiotic' nomogram and the SeBA-GEN and DoseCalc software programs: 521
MOHER, D. *see* MILLS, E.
MONTERO, D. *see* DE ABAJO, F.J.
MONTORI, V.M. *see* MILLS, E.
MOROCHO, A. *see* WARD, B.A.
MORRISON, M.F. *see* HENNESSY, S.
MOUELHI, M.E., WORLEY, D.J., KUZMAK, B., DESTEFANO, A.J. & THOMPSON, G.A. Influence of ketoconazole on azimilide pharmacokinetics in healthy subjects: 641
MOURAD, L. *see* VAN ROON, E.N.
MOUSA, S.A. Anticoagulants, antiplatelets and thrombolytics: 442
MULDER, H. *see* UCHIDA, T.
MUSTAFA, A.M. *see* YANG, Y.S.

NAGASHIMA, S. *see* TOGAWA, A.
NAJEM, M. *see* KAMBAL, A.
NAKAMURA, H. *see* ARIYOSHI, N.
NAKAMURA, T. *see* KAWAGUCHI, A.
NARJES, H. *see* GUTH, B.D.
NAS, T. *see* OKUMUS, N.
NEHMIZ, G. *see* GUTH, B.D.
NEL, J.E. *see* VAN OPSTAL, J.M.
NEUVONEN, M. *see* KAJOSAARI, L.I.
NEUVONEN, M. *see* LILJA, J.J.
NEUVONEN, P.J. *see* KAJOSAARI, L.I.
NEUVONEN, P.J. *see* LILJA, J.J.
NEWCOMBE, D. *see* MITCHELL, T.B.
NIBBERING, P.H. *see* LITJENS, N.H.R.
NISHIKAWA, Y. *see* TOGAWA, A.
NISHIKI, K. *see* KAWAGUCHI, A.
NISHIMURA, M. *see* ARIYOSHI, N.
NORDVALL, S.L. *see* KAAE, R.

ÖNAL, E.E. *see* OKUMUS, N.
O'REGAN, L. *see* ISBISTER, G.K.
ODUBANJO, E., BENNETT, K. & FEELY, J. Influence of socioeconomic status on the quality of prescribing in the elderly – a population based study: 496
OHKUBO, T. *see* OSANAI, T.
OHMORI, M. *see* KAWAGUCHI, A.
OKUMUS, N., TÜRKYILMAZ, C., ÖNAL, E.E., ATALAY, Y., KOÇ, E. & NAS, T. Ritodrine-induced transient neutropenia in newborn twins after *in utero* exposure: Report of first cases: 445
OLSEN, L., CHRISTOPHERSEN, A.S., FROGOPSAHL, G., WAAL, H. & MØRLAND, J. Plasma concentrations during naltrexone implant treatment of opiate-dependent patients: 219
ONYEJI, C.O. *see* BASSI, P.U.
ORNOY, A. *see* BERKOVITCH, M.
OSANAI, T., OHKUBO, T., YASUI, N., KONDO, T. & KANEKO, S. Effect of itraconazole on the pharmacokinetics and pharmacodynamics of a single oral dose of brotizolam: 476
OSSELTON, M.D. *see* MOFFATT, A.C.
OTT, P.M. *see* BAUMANN, C.R.

PAINTER, C.J. *see* CANTARINI, M.V.
PARK, J.-Y., KIM, K.-A., SHIN, J.-G. & LEE, K.Y. Effect of ketoconazole on the pharmacokinetics of rosiglitazone in healthy subjects: 397
PEDERSEN, S. *see* KAAE, R.
PEDROLETTI, C. *see* KAAE, R.
PERLOFF, E.S. *see* MAI, I.
PERRI, D. *see* MILLS, E.
PETERSEN, S. *see* SMYTH, J.M.
PILLAI, G., GIESCHKE, R., GOGGIN, T., JACQMIN, P., SCHIMMER, R.C. & STEIMER, J.-L. A semimechanistic and mechanistic population PK–PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis: 618
PILOTE, S. *see* SHARMA, A.
PISTOLESI, M. *see* LAVORINI, F.
POHL, J.E.F. *see* CREAN, A.M.
POHLE, T. *see* BECKER, J.C.
POLI, G. *see* HOUGHTON, C.M.
PRAHARAJ, S.K. Serotonin reuptake inhibitor induced sensory disturbances: 673
PRETI, A.P.M. *see* HOUGHTON, C.M.
Professor BEGG, E.J. Individualizing drug therapy, and 'men behaving badly': 449
PUD, D. *see* GRACH, M.
PURDIE, D.M. *see* SORENSEN, L.

RANE, A. *see* LINDH, J.D.
RAWLINS, M.D. NICE and the public health: 575
REICH, L. *see* HAUBEN M.
REICH, L. *see* HAUBEN, M.
REYNOLDS, R.F. *see* HENNESSY, S.
RIEDEL, A. *see* GUTH, B.D.
RIEDEL, K.-D. *see* MARTIN-FACKLAM, M.
RIEGER, K. *see* MARTIN-FACKLAM, M.
RIIS, A. *see* AGERSØ, H.
RITTER, J.M. *see* BABER, N.S.
ROBB, F.M. *see* LEE, D.K.C.
ROBERTS, M.S. *see* SORENSEN, L.
RODRÍGUEZ, L.A.G. *see* DE ABAJO, F.J.
RODRIGUEZ, S. *see* MANGONI, A.A.
ROOTS, I. *see* MAI, I.
ROSENBORG, J. *see* KAAE, R.
RYLANCE, G. *see* CHOONARA, I.

SAITO, T. *see* TSURUOKA, S.
SAITOH, Y. *see* ARIYOSHI, N.
SALTER, A. *see* MITCHELL, T.B.
SANDERSON, J.B. *see* SOBUE, S.
SCHIMMER, R.C. *see* PILLAI, G.
SCHMITT, M. *see* SHARMAN, J.E.
SCHOEMAKER, R.C. *see* LITJENS, N.H.R.
SCHUBERT, H.-D. *see* GUTH, B.D.
SCHUMACHER, M.M. *see* KRETZ, O.
SENDEROVITZ, T. *see* AGERSØ, H.
SHAH, R.R. Drug development and use in the elderly: search for the right dose and dosing regimen: 452
SHALTS, E. & SHIFLETT, S. The conclusion that 'ultramolecular homeopathy has no observable clinical effects' is not supported by the data: 340
SHARMA, A., PILOTE, S., BÉLANGER, P.M., ARSENAULT, M. & HAMELIN, B.A. A convenient five-drug cocktail for the assessment of major drug metabolizing enzymes: a pilot study: 288
SHARMAN, J.E., GUNARUWAN, P., KNEZ, W.L., SCHMITT, M., MARSH, S.A., WILSON, G.R., COCKCROFT, J.R. & COOMBES, J.S. Alpha-lipoic acid does not acutely affect resistance and conduit artery function or oxidative stress in healthy men: 243
SHECHTMAN, S. *see* BERKOVITCH, M.
SHEFFELS, P. *see* DALE, O.
SHERWOOD, R.A. *see* MANGONI, A.A.
SHIFLETT, S. *see* SHALTS, E.
SHIN, J.-G. *see* PARK, J.-Y.
SHINFUKU, N. *see* SIM, K.
SHO-NO, K. *see* ARIYOSHI, N.
SI, T. *see* SIM, K.
SIBBRITT, D. *see* ISBISTER, G.K.
SIEGEL, A.M. *see* BAUMANN, C.R.
SIM, K., SU, A., FUJII, S., YANG, S.-Y., CHONG, M.-Y., UNGVARI, G.S., SI, T., CHUNG, E.K., TSANG, H.-Y., CHAN, Y.H., HECKERS, S., SHINFUKU, N. & TAN, C.H. Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia: 178
SINGH, D. *see* HOUGHTON, C.M.
SINGH, S.D. *see* HOUGHTON, C.M.
SMULDERS, R.A. *see* UCHIDA, T.
SMYTH, J.M., COLLIER, P.S., DARWISH, M., MILLERSHIP, J.S., HALLIDAY, H.L., PETERSEN, S. & MCELNAY, J.C. Intravenous indometacin in preterm infants with symptomatic patent ductus arteriosus. A population pharmacokinetic study: 249

SOBUE, S., TAN, K., LAYTON, G., EVE, M. & SANDERSON, J.B. Pharmacokinetics of fosfluconazole and fluconazole following multiple intravenous administration of fosfluconazole in healthy male volunteers: 20
SOMOGYI, A.A. *see* JITTIWUTIKARN, J.
SOMOGYI, A.A. *see* MITCHELL, T.B.
SORENSEN, L., STOKES, J.A., PURDIE, D.M., WOODWARD, M., ELLIOTT, R. & ROBERTS, M.S. Medication reviews in the community: results of a randomized, controlled effectiveness trial: 648
SOUTAR, P.C. *see* LEE, D.K.C.
SRIMARTPIROM, S., TASSANEEYAKUL, W., KUKONGVIRIYAPAN, V. & TASSANEEYAKUL, W. Thiopurine S-methyltransferase genetic polymorphism in the Thai population: 66
STEIMER, J.-L. *see* PILLAI, G.
STITZEL, R.E. *see* CRAIG, C.R.
STOKES, J.A. *see* SORENSEN, L.
STROM, B.L. *see* HENNESSY, S.
STRUTHERS, A.D. *see* WITHAM, M.D.
SU, A. *see* SIM, K.
SWIFT, C.G. *see* MANGONI, A.A.

TALBOT, J. & WALLER, P. Stephens' Detection of New Adverse Drug Reactions, 5th edn: 227
TAN, C.H. *see* SIM, K.
TAN, K. *see* SOBUE, S.
TANAKA, H. *see* TOGAWA, A.
TANAKA, T. *see* TOGAWA, A.
TANSWELL, P. *see* GUTH, B.D.
TASSANEEYAKUL, W. *see* SRIMARTPIROM, S.
TASSANEEYAKUL, W. *see* SRIMARTPIROM, S.
TAYROUZ, Y. *see* FRICKER, R.
TETT, S.E. *see* DELDOT, M.E.
THIO, H.B. *see* LITJENS, N.H.R.
THOMPSON, G.A. *see* MOUELHI, M.E.
THOMSON, A.H. *see* WÄHLBY, U.
TOBI, H. *see* VAN ROON, E.N.
TOGAWA, A., TANAKA, T., NAGASHIMA, S., KETA, H., KOBAYASHI, Y., NISHIKAWA, Y., YANAI, M. & TANAKA, H. A comparison of the bioequivalence of two formulations of epoetin alfa after subcutaneous injection: 269
TOMLINSON, B. *see* CHENG, C.W.R.
TSANG, H.-Y. *see* SIM, K.
TSURUOKA, S. *see* KAWAGUCHI, A.
TSURUOKA, S., YAMAMOTO, H., IOKA, T., ANDO, H., SAITO, T. & FUJIMURA, A. Adsorption of oxacalcitriol by polysulphone haemodialyser in patients with secondary hyperparathyroidism: 488
TÜRKYILMAZ, C. *see* OKUMUS, N.

UCHIDA, T., KRAUWINKEL, W.J., MULDER, H. & SMULDERS, R.A. Food does not affect the pharmacokinetics of solifenacin, a new muscarinic receptor antagonist: results of a randomized crossover trial: 4
UKPONMWAN, O.E. *see* BASSI, P.U.
UNGVARI, G.S. *see* SIM, K.
UNNEBRINK, K. *see* FRICKER, R.

VALLANCE, P. *see* CHOONARA, I.
VAN DISSEL, J.T. *see* LITJENS, N.H.R.
VAN GULPEN, C. *see* LITJENS, N.H.R.
VAN OPSTAL, J.M., JANKNEGT, R., CILISSEN, J., L'ORTIJE, W.H.V.M., NEL, J.E. & DE HEER, F. Severe overdosage with the antiepileptic drug oxcarbazepine: 329
VAN ROON, E.N., JANSEN, T.L.T.A., MOURAD, L., HOUTMAN, P.M., BRUYN, G.A.W., GRIEP, E.N., WILFFERT, B., TOBI, H. & BROUWERS, J.R.B.J. Leflunomide in active rheumatoid arthritis: a prospective study in daily practice: 201
VAN STRIJEN, E. *see* LITJENS, N.H.R.
VANDER STICHELE, R.H., ELSEVIERS, M.M., FERECH, M., BLOT, S. & GOOSSENS, H. European Surveillance of Antimicrobial Consumption (ESAC): Data Collection Performance and Methodological Approach: 419
VERSCHUREN, W.M.M. *see* MANTEL-TEEUWISSE, A.K.
VONCKEN, D.S. *see* LA PORTE, C.J.L.

WÄHLBY, U., THOMSON, A.H., MILLIGAN, P.A. & KARLSSON, M.O. Models for time-varying covariates in population pharmacokinetic-pharmacodynamic analysis: 367
WAAL, H. *see* OLSEN, L.
WALKER, D.K. The use of pharmacokinetic and pharmacodynamic data in the assessment of drug safety in early drug development: 601
WALLER, P. *see* TALBOT, J.
WALTER-SACK, I. *see* MARTIN-FACKLAM, M.
WARD, B.A., MOROCHO, A., KANDIL, A., GALINSKY, R.E., FLOCKHART, D.A. & DESTA, Z. Characterization of human cytochrome P450 enzymes catalyzing domperidone N-dealkylation and hydroxylation *in vitro*: 277
WARHOLM, M. *see* ERNSTGÅRD, L.
WATKINS, C.L. *see* CANTARINI, M.V.
WEISS, H.M. *see* KRETZ, O.
WEISS, J. *see* FRICKER, R.
WEISS, J. *see* FRÖHLICH, M.
WESTGREN, M. *see* LINDH, J.D.
WHITE, J.M. *see* JITTIWUTIKARN, J.
WHITE, J.M. *see* MITCHELL, T.B.
WHYTE, I.M. *see* ISBISTER, G.K.
WIDDOP, B. *see* MOFFATT, A.C.
WILFFERT, B. *see* VAN ROON, E.N.
WILLIAMS, D., BENNETT, K. & FEELY, J. Prescribing for osteoporosis following the use of inhaled and oral glucocorticoids in general practice: 665
WILSON, A.M. *see* LEE, D.K.C.
WILSON, G.R. *see* SHARMAN, J.E.
WITHAM, M.D., GILLESPIE, N.D. & STRUTHERS, A.D. Tolerability of spironolactone in patients with chronic heart failure – a cautionary message: 554
WOJNAR-HORTON, R.E. *see* MOHAN, M.
WONG, L.P. *see* YANG, Y.S.
WOO, K.-S. *see* CHENG, C.W.R.
WOODCOCK, A. *see* HOUGHTON, C.M.
WOODCOCK, A.A. *see* HOUGHTON, C.M.
WOODWARD, M. *see* SORENSEN, L.
WORLEY, D.J. *see* MOUELHI, M.E.
WU, J.-H. *see* ZHANG, J.-P.
WU, P. *see* MILLS, E.

XU, A.-L. *see* ZHANG, J.-P.

YAMAMOTO, H. *see* TSURUOKA, S.
YANAI, M. *see* TOGAWA, A.
YANG, S.-Y. *see* SIM, K.
YANG, Y.S., WONG, L.P., LEE, T.C., MUSTAFA, A.M., MOHAMED, Z. & LANG, C.C. Genetic polymorphism of cytochrome P450 2C19 in healthy Malaysian subjects: 332
YANO, R. *see* KAWAGUCHI, A.
YASUI, N. *see* OSANAI, T.
YOU, J.H.S. *see* CHENG, C.W.R.

ZHANG, J.-P., GUAN, Y.-Y., WU, J.-H., XU, A.-L., ZHOU, S. & HUANG, M. Phenotyping and genotyping study of thiopurine S-methyltransferase in healthy Chinese children: A comparison of Han and Yao ethnic groups: 163
ZHOU, S. *see* ZHANG, J.-P.
ZINGMARK, P.-H., EDENIUS, C. & KARLSSON, M.O. Pharmacokinetic/pharmacodynamic models for the depletion of Vβ5.2/5.3 T cells by the monoclonal antibody ATM-027 in patients with multiple sclerosis, as measured by FACS: 378

DOI:10.1111/j.1365-2125.2004.02349.x

SUBJECT INDEX

This index was compiled from the keywords

α-acid glycoprotein, 212
adenosine monophosphate, 34
adsorption, 488
aged, 554
aliskiren, 433
alprazolam, 88
aminoglycosides, 8
amiodarone, 96
amoxycillin, 298
Anti-bacterial agents, 419
antibiotic treatment, 184
antibiotics, 259
antihypertensive drugs, 581
antilipaemic agents, 310
antioxidant enzymes, 542
antiplatelet drugs, 581
antipsychotic, 178
antipsychotic agents, 81
arrhythmia, 81
Asia, 178
aspirin, 587
asthma, 26, 512
asthma diary, 26
atopic asthma, 34
azimilide, 641

benzodiazepines, 88
bezafibrate, 390
bias in clinical trials, 581
bioadhesive tablet, 345
bioavailability, 20, 156
bioequivalence, 269
bleeding time, 40
body build, 190
body mass index, 119
body surface area, 119
body weight, 119
bronchial hyper-responsiveness, 34
bronchodilation, 512
bronchoprotection, 359
brotizolam, 476

caffeine, 288
cardiovascular diseases, 310
CGP74587, 212
Children, 411
Chinese patients, 528
chlorzoxazone, 190, 288
ciclesonide, 26
clinical pharmacology, 61, 217
clinical trial simulation, 142
clinical trial simulations, 378
clinical value compass, 648
cocktail, 288
cohort studies, 81
cold pressor test, 235
combined endpoints, 581
community pharmacy services, 503, 648
comparative, 178
comparators, 581
congestive, 554
continuous renal replacement therapy, 259
covariate, 367
COX/5-LOX, 587
CYP1A2, 288
CYP2C8, 397
CYP2C9, 288
CYP2D6, 288
CYP2E1, 190
CYP2E1, 288
CYP3A4 inhibition, 641
CYP3A4, 288, 403, 476
Cytochrome P450 2C19 polymorphism Malaysian, 332
cytochrome P450, 277
cytochrome P450s, 288

dapsone, 288
Data collection, 419
data collection/methods, 482
DDAVP, 352
decreased libido, 326
decreased testosterone, 326
desmopressin, 352
domperidone, 277
dose dependence, 190
DoseCalc, 521
drug discovery, 601
drug interaction, 397, 433, 476
drug safety, 601
drug therapy, 310
Drug utilization, 419
drug-induced liver injury, 71
drug-related problem, 503
dry-powder inhalers, 512
dyspnoea, 512

efavirenz, 632
effectiveness trial, 648
elderly, 496
enantiomeric ratio, 609
endogenous, 269
endothelial function, 169
endothelial nitric-oxide synthase, 169
epoetin, 269
erythropoietin, 269
ethanol, 190
Europe, 419
evaluation studies, 503
exhaled nitric oxide, 26

FACS, 378
Factual databases, 419
fenofibrate, 390
fluconazole, 20
fluticasone, 26
follow-up, 209
food ingestion, 4
food–drug interaction, 56
formoterol, 359, 411
fosfluconazole, 20
Free radicals, 243
fumarates, 429

general practice, 665
genetic polymorphism, 66
genotype, 163
gentamicin, 521
Gleevec™, 212
Glivec®, 212
glutathione peroxidase, 542
glutathione reductase, 542
GPRD, 303
grapefruit juice, 56

H. pylori, 587
haeme-oxygenase, 587
haemodialyser, 488
Haemodynamics, 243
halofantrine, 52
haplotype, 548
heart failure, 554
hepatoxicity, 71
high-performance liquid chromatography, 429
histamine H_1-receptor antagonist, 34
home care services, 648
hospitalisation, 437
human, 156, 190
hydrofluoroalkane formulations, 26
hydrofluoroalkane inhaler, 359
6-hydroxychlorzoxazone, 190
hydroxylation, 277
Hydroxymethylglutaryl-CoA Reductase Inhibitors, 326
hypercholesterolaemia, 310
Hypericum, 437

ibandronate, 618
imatinib mesylate, 212
implant, 219
in vitro fertilization, 209
indometacin, 249
induction, 142
influence analysis, 142
inhaled corticosteroid, 26
inhaled corticosteroids, 665

© 2004 Blackwell Publishing Ltd

interaction, 52, 390
Internet, 482
intervention, 503
intravenous, 156
Iohexol, 96
itraconazole, 476

ketoconazole, 397, 641
κ-opioid agonist, 235

LDL reduction, 528
leflunomide, 201
levocetirizine, 34
linezolid, 470
Lipoic acid, 243
loading dose, 20
logistic regression, 378
long QT syndrome, 96
lung function, 26
lung function tests, 134

malformations, 298
MDR1, 548
melatonin, 542
metabolic ratio, 190
metabolites, 156, 277
methacholine, 26
Methadone, 156
methadone, 536, 609
methodology, 61
metoprolol, 288
miconazole, 345
Microbial drug resistance, 419
mini asthma quality of life questionnaire, 26
modelling and simulation, 618
monoamine oxidase inhibitor, 470
monoclonal antibody, 378
monomethylfumarate, 429
Monte Carlo simulation, 142
mood, 609
μ-opioid agonist, 235
moxycillin/clavulanic acid, 298
multicentre studies, 482
muscarinic receptor antagonist, 4

N-acetyltransferase, 288
NADPH oxidase polymorphism (C242T), 169
naltrexone, 219
nelfinavir, 632
nitric oxide, 169
nitrofurantoin, 184
non-linear mixed effects models, 378
nonlinear mixed effects, 352
NONMEM, 142, 352, 367, 618
NO-NSAID, 587
NOSIII polymorphisms (G894T, T-786C and (CA)n), 169
nucleoside-sparing, 632

obesity, 119
once-daily, 632
opioid dependence, 219
opioid withdrawal, 536
oral, 156
oral glucocorticoids, 665
osteoporosis, 618, 665
overactive bladder, 4
overdose, 88
oxacalcitriol, 488
oxcarbazepine, 329

paediatrics, 217
pain magnitude, 235
pain threshold, 235
pain tolerance, 235
patent ductus arteriosus, 249
patient adherence, 528
patient care team, 648
patients, 548
P-glycoprotein, 548
pharmaceutical care, 503
pharmacist, 503
pharmacodynamics, 378, 601, 618
pharmacoepidemiology, 81, 496
pharmacokinetics, 4, 20, 52, 119, 156, 259, 269, 345, 352, 378, 397, 429, 476, 548, 601, 618, 632, 641
phenotype, 163
plasma levels, 219
platelet aggregation, 40
polypharmacy, 178
polysulphone, 488
population pharmacokinetics, 8, 249
PPI, 587
pravastatin, 303
pregnancy, 298
prescription, 503
prescription error, 503
prescription modification, 503
preterm infants, 249
prodrug, 329
prokinetic, 277
proportional odds model, 378
psoriasis, 429
pupillometry, 156

quality prescribing, 496
quazepam, 403

randomized controlled trials, 61, 648
rectal, 156
renal impairment, 352
renin inhibitor, 433
repaglinide, 390
reporting quality, 61
retinoblastoma, 209
reversibility technique, 134
rheumatoid arthritis, 201

ritonavir, 632
rosiglitazone, 397

saturable absorption, 142
schizophrenia, 178
SeBA-GEN, 521
secondary hyperparathyroidism, 488
self-medication, 437
simvastatin, 56
small airways, 512
socioeconomic status, 496
solid tumours, 142
solifenacin succinate, 4
spacers, 512
spironolactone, 554
St. John's Wort, 403
statin, 528
statins, 303
stereoisomers, 609
surrogate endpoints, 581

tacrolimus, 548
target concentration intervention, 8
teratogenicity, 298
terbogrel, 40
terbutaline, 411
tetracycline, 52
Thai, 66
Thailand, 536
therapeutic drug monitoring, 521
Therapeutic Guidelines: Antibiotic, 521
thiopurine S-methyltransferase, 66, 163
thromboxane receptor, 40
thromboxane synthase, 40
time-varying, 367
tincture of opium, 536
tolbutamide, 288
tolerability, 411
torsade de pointes tachycardia, 96
toxicity, 88, 329
*TPMT*3C*, 163
TPMT, 66
training, 217
treatment failure, 184
trimethoprim, 184
Type II diabetes, 303
tyramine pressor test, 470

urinary excretion, 352
urinary tract infection, 184

valproate, 542
vancomycin, 259
volunteers, 156

warfarin, 433, 482
withdrawal, 609

YM905, 4